SCHEMBL18151197

SCHEMBL18151197

O=C(Cc1ccc(S(=O)(=O)NC2CC2)cc1)Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RORC P51449 12/20 0.67
MAPT P10636 1/20 0.53
CYP2D6 P10635 2/20 0.53
MEN1 O00255 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
GAA P10253 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
KMT2A Q03164 1/20 0.49
NAMPT P43490 1/20 0.49
POLB P06746 1/20 0.48
TSHR P16473 1/20 0.47
RORA P35398 1/20 0.47
KDM4E B2RXH2 1/20 0.47
PKM P14618 1/20 0.47
MLYCD O95822 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18151610 0.96 RORC (0.65) RORCMAPTCYP2D6MEN1CYP1A2
SCHEMBL18151510 0.89 RORC (0.56) RORCMAPTCYP2D6MEN1CYP1A2
SCHEMBL18151589 0.88 RORC (0.57) RORCMAPTCYP2D6MEN1CYP1A2
SCHEMBL18151519 0.88 RORC (0.54) RORCMAPTCYP2D6MEN1KMT2A
SCHEMBL18151422 0.88 POLB (0.53) RORCMAPTCYP2D6MEN1CYP1A2
SCHEMBL18151837 0.87 MAPT (0.54) RORCMAPTCYP2D6MEN1CYP1A2
SCHEMBL18151763 0.87 RORC (0.56) RORCMAPTCYP2D6MEN1CYP1A2
SCHEMBL18151716 0.86 RORC (0.55) RORCMAPTCYP2D6MEN1CYP1A2
SCHEMBL18151186 0.86 RORC (0.53) RORCMAPTCYP2D6MEN1CYP1A2
SCHEMBL18151715 0.85 RORC (0.65) RORCMAPTMEN1KMT2ANAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3077372-B1 ROR GAMMA (RORY) MODULATORS LEAD PHARMA HOLDING BV (NL) 2019-02-06 EP claimed
US-9738600-B2 ROR gamma (RORγ) modulators LEAD PHARMA CEL MODELS IP B.V. (NL) 2017-08-22 US claimed
US-20160304448-A1 ROR GAMMA (RORy) MODULATORS LEAD PHARMA CEL MODELS IP B.V. (NL) 2016-10-20 US claimed
EP-3077372-B1 ROR GAMMA (RORY) MODULATORS LEAD PHARMA HOLDING BV (NL) 2019-02-06 EP disclosed
US-9738600-B2 ROR gamma (RORγ) modulators LEAD PHARMA CEL MODELS IP B.V. (NL) 2017-08-22 US disclosed
US-9738600-B2 ROR gamma (RORγ) modulators LEAD PHARMA CEL MODELS IP B.V. (NL) 2017-08-22 US disclosed
US-20160304448-A1 ROR GAMMA (RORy) MODULATORS LEAD PHARMA CEL MODELS IP B.V. (NL) 2016-10-20 US disclosed
US-20160304448-A1 ROR GAMMA (RORy) MODULATORS LEAD PHARMA CEL MODELS IP B.V. (NL) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304448-A1 ROR GAMMA (RORy) MODULATORS RORC, RORA, RORB RORC 1/4885MAPT 4664/4885CYP2D6 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.